Open Access

Cells

, volume 11 , issue 5 , pages 770

Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era

Laura Kalfeist ^{1, 2}

Loïck Galland ^{1, 2, 3}

Fanny Ledys ^{1, 2}

François Ghiringhelli ^{1, 2, 3, 4}

Emeric Limagne ^{1, 2}

Sylvain Ladoire ^{1, 2, 3, 4}

Hide authors affiliations Show authors affiliations: 4 affiliations

Platform of Transfer in Cancer Biology, Georges-Francois Leclerc Center, 21000 Dijon, France |

UMR INSERM 1231 “Lipides Nutrition Cancer”, 21000 Dijon, France |

Department of Medical Oncology, Georges-François Leclerc Center, 21000 Dijon, France |

⁴

School of Medicine, University of Burgundy Franche-Comté, 21000 Dijon, France |

Publication type: Journal Article

Publication date: 2022-02-22

MDPI

Cells

scimago Q1

wos Q2

SJR: 1.670

CiteScore: 10.5

Impact factor: 5.2

ISSN: 20734409

DOI: 10.3390/cells11050770

Copy DOI

PubMed ID: 35269392

General Medicine

Abstract

Thanks to their anti-inflammatory, anti-oedema, and anti-allergy properties, glucocorticoids are among the most widely prescribed drugs in patients with cancer. The indications for glucocorticoid use are very wide and varied in the context of cancer and include the symptomatic management of cancer-related symptoms (compression, pain, oedema, altered general state) but also prevention or treatment of common side effects of anti-cancer therapies (nausea, allergies, etc.) or immune-related adverse events (irAE). In this review, we first give an overview of the different clinical situations where glucocorticoids are used in oncology. Next, we describe the current state of knowledge regarding the effects of these molecules on immune response, in particular anti-tumour response, and we summarize available data evaluating how these effects may interfere with the efficacy of immunotherapy using immune checkpoint inhibitors.

Found

1 citation

Lesovaya Ekaterina

73 publications, 690 citations

h-index: 15

Ryazan State Medical University named after Academician I.P. Pavlov

N.N. Blokhin National Medical Research Center of Oncology

1 citation

Moschopoulos Charalampos

33 publications, 594 citations, 47 reviews

h-index: 12

National and Kapodistrian University of Athens

Research interests

Antimicrobial resistance

Top-30

Journals

	1 2 3
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 3, 5.45% International Journal of Molecular Sciences 3 publications, 5.45%
Cancers	Cancers, 3, 5.45% Cancers 3 publications, 5.45%
Cells	Cells, 2, 3.64% Cells 2 publications, 3.64%
Frontiers in Oncology	Frontiers in Oncology, 2, 3.64% Frontiers in Oncology 2 publications, 3.64%
Biochemical Pharmacology	Biochemical Pharmacology, 1, 1.82% Biochemical Pharmacology 1 publication, 1.82%
Critical Reviews in Oncology/Hematology	Critical Reviews in Oncology/Hematology, 1, 1.82% Critical Reviews in Oncology/Hematology 1 publication, 1.82%
npj Precision Oncology	npj Precision Oncology, 1, 1.82% npj Precision Oncology 1 publication, 1.82%
JCEM Case Reports	JCEM Case Reports, 1, 1.82% JCEM Case Reports 1 publication, 1.82%
OncoImmunology	OncoImmunology, 1, 1.82% OncoImmunology 1 publication, 1.82%
Translational Cancer Research	Translational Cancer Research, 1, 1.82% Translational Cancer Research 1 publication, 1.82%
Ca-A Cancer Journal for Clinicians	Ca-A Cancer Journal for Clinicians, 1, 1.82% Ca-A Cancer Journal for Clinicians 1 publication, 1.82%
Current Treatment Options in Cardiovascular Medicine	Current Treatment Options in Cardiovascular Medicine, 1, 1.82% Current Treatment Options in Cardiovascular Medicine 1 publication, 1.82%
Pharmaceutics	Pharmaceutics, 1, 1.82% Pharmaceutics 1 publication, 1.82%
Journal of Palliative Care	Journal of Palliative Care, 1, 1.82% Journal of Palliative Care 1 publication, 1.82%
Methods in Molecular Biology	Methods in Molecular Biology, 1, 1.82% Methods in Molecular Biology 1 publication, 1.82%
CONTINUUM Lifelong Learning in Neurology	CONTINUUM Lifelong Learning in Neurology, 1, 1.82% CONTINUUM Lifelong Learning in Neurology 1 publication, 1.82%
Physical Biology	Physical Biology, 1, 1.82% Physical Biology 1 publication, 1.82%
Expert Opinion on Drug Safety	Expert Opinion on Drug Safety, 1, 1.82% Expert Opinion on Drug Safety 1 publication, 1.82%
Radiology and Oncology	Radiology and Oncology, 1, 1.82% Radiology and Oncology 1 publication, 1.82%
Cellular and Molecular Life Sciences	Cellular and Molecular Life Sciences, 1, 1.82% Cellular and Molecular Life Sciences 1 publication, 1.82%
Journal of Cancer Research and Clinical Oncology	Journal of Cancer Research and Clinical Oncology, 1, 1.82% Journal of Cancer Research and Clinical Oncology 1 publication, 1.82%
Translational Oncology	Translational Oncology, 1, 1.82% Translational Oncology 1 publication, 1.82%
Frontiers in Immunology	Frontiers in Immunology, 1, 1.82% Frontiers in Immunology 1 publication, 1.82%
Heliyon	Heliyon, 1, 1.82% Heliyon 1 publication, 1.82%
Journal of Steroid Biochemistry and Molecular Biology	Journal of Steroid Biochemistry and Molecular Biology, 1, 1.82% Journal of Steroid Biochemistry and Molecular Biology 1 publication, 1.82%
Supportive Care in Cancer	Supportive Care in Cancer, 1, 1.82% Supportive Care in Cancer 1 publication, 1.82%
Frontiers in Endocrinology	Frontiers in Endocrinology, 1, 1.82% Frontiers in Endocrinology 1 publication, 1.82%
Bioscience Reports	Bioscience Reports, 1, 1.82% Bioscience Reports 1 publication, 1.82%
Clinical Microbiology and Infection	Clinical Microbiology and Infection, 1, 1.82% Clinical Microbiology and Infection 1 publication, 1.82%
	1 2 3

Publishers

	2 4 6 8 10 12
Springer Nature	Springer Nature, 11, 20% Springer Nature 11 publications, 20%
MDPI	MDPI, 9, 16.36% MDPI 9 publications, 16.36%
Elsevier	Elsevier, 8, 14.55% Elsevier 8 publications, 14.55%
Frontiers Media S.A.	Frontiers Media S.A., 5, 9.09% Frontiers Media S.A. 5 publications, 9.09%
Wiley	Wiley, 4, 7.27% Wiley 4 publications, 7.27%
Taylor & Francis	Taylor & Francis, 2, 3.64% Taylor & Francis 2 publications, 3.64%
AME Publishing Company	AME Publishing Company, 2, 3.64% AME Publishing Company 2 publications, 3.64%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 2, 3.64% Ovid Technologies (Wolters Kluwer Health) 2 publications, 3.64%
Research Square Platform LLC	Research Square Platform LLC, 2, 3.64% Research Square Platform LLC 2 publications, 3.64%
BMJ	BMJ, 2, 3.64% BMJ 2 publications, 3.64%
The Endocrine Society	The Endocrine Society, 1, 1.82% The Endocrine Society 1 publication, 1.82%
SAGE	SAGE, 1, 1.82% SAGE 1 publication, 1.82%
IOP Publishing	IOP Publishing, 1, 1.82% IOP Publishing 1 publication, 1.82%
Walter de Gruyter	Walter de Gruyter, 1, 1.82% Walter de Gruyter 1 publication, 1.82%
Portland Press	Portland Press, 1, 1.82% Portland Press 1 publication, 1.82%
American Medical Association (AMA)	American Medical Association (AMA), 1, 1.82% American Medical Association (AMA) 1 publication, 1.82%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 1, 1.82% Cold Spring Harbor Laboratory 1 publication, 1.82%
	2 4 6 8 10 12

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

PDF

Metrics

Cite this

GOST |

Cite this

GOST Copy

Kalfeist L. et al. Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era // Cells. 2022. Vol. 11. No. 5. p. 770.

GOST all authors (up to 50) Copy

Kalfeist L., Galland L., Ledys F., Ghiringhelli F., Limagne E., Ladoire S. Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era // Cells. 2022. Vol. 11. No. 5. p. 770.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.3390/cells11050770

UR - https://doi.org/10.3390/cells11050770

TI - Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era

T2 - Cells

AU - Kalfeist, Laura

AU - Galland, Loïck

AU - Ledys, Fanny

AU - Ghiringhelli, François

AU - Limagne, Emeric

AU - Ladoire, Sylvain

PY - 2022

DA - 2022/02/22

PB - MDPI

SP - 770

IS - 5

VL - 11

PMID - 35269392

SN - 2073-4409

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2022_Kalfeist,

author = {Laura Kalfeist and Loïck Galland and Fanny Ledys and François Ghiringhelli and Emeric Limagne and Sylvain Ladoire},

title = {Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era},

journal = {Cells},

year = {2022},

volume = {11},

publisher = {MDPI},

month = {feb},

url = {https://doi.org/10.3390/cells11050770},

number = {5},

pages = {770},

doi = {10.3390/cells11050770}

}

MLA

Cite this

MLA Copy

Kalfeist, Laura, et al. “Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era.” Cells, vol. 11, no. 5, Feb. 2022, p. 770. https://doi.org/10.3390/cells11050770.

Publisher

MDPI

Journal

Cells

scimago Q1

wos Q2

SJR

1.670

CiteScore

10.5

Impact factor

5.2

ISSN

20734409 (Print, Electronic)